martedì, 5 maggio 2026

Notizie AIOM – anno XV

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to evaluate the safety and efficacy of pembrolizumab, an anti-programmed death 1 monoclonal antibody, in patients with programmed death ligand 1 (PD-L1) -positive advanced solid tumors. The results from ...
Leggi tutto

ASTRO Issues Guideline for Use of Stereotactic Radiation in Early-Stage Lung Cancer

June 15, 2017 - The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the use of stereotactic body radiation therapy (SBRT) in early-stage lung cancer. While SBRT is the current standard of care for peripherally located tumors in patients ...
Leggi tutto

ASCO Says Senate Healthcare Bill Is a Disappointment

June 22, 2017 - Senate Republicans have introduced a healthcare bill that would revise many of the changes imposed by the Patient Protection and Affordable Care Act (ACA), cutting federal support for Medicaid and repealing the individual and employer mandates for having ...
Leggi tutto

NCCN Guidelines® Compliance for Chest CT May Reduce False Positives and Decrease Health-Care Spending in Breast Cancer

June 23, 2017 - According to Surveillance, Epidemiology, and End Results (SEER) data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease. For this demographic, the National ...
Leggi tutto

Copanlisib Lymphoma Data Updated as FDA Considers Approval

June 17, 2017 - Copanlisib showed an objective response rate (ORR) of 59.2% (95% CI, 50.6%-67.3%) without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma, according to findings from the ...
Leggi tutto

FDA Accepts Denosumab sBLA for Multiple Myeloma

June 19, 2017 - The FDA has accepted a supplemental biologics license application (sBLA) for the use of denosumab for the prevention of skeletal-related events (SREs) in patients with multiple myeloma, according to Amgen, the developer of the RANK ligand inhibitor. The sBLA ...
Leggi tutto

FDA Approves Aminolevulinic Acid Hydrochloride as an Optical Imaging Agent Indicated in Gliomas

June 20, 2017 - On June 6, the U.S. Food and Drug Administration (FDA) approved aminolevulinic acid hydrochloride, known as ALA HCl, as an optical imaging agent indicated in patients with gliomas (suspected World Health Organization Grades III or IV) for preoperative imaging, ...
Leggi tutto

FDA Approval Sought for Brentuximab Vedotin in CTCL

June 21, 2017 - A supplemental Biologics License Application (sBLA) has been submitted to the FDA for brentuximab vedotin as a treatment for patients with cutaneous T-cell lymphoma (CTCL), according to Seattle Genetics, which codevelops the antibody-drug conjugate with Takeda. ...
Leggi tutto

FDA Grants Orphan Drug Status to Tazemetostat for Soft Tissue Sarcoma

June 21, 2017 - Epizyme announced today that the FDA has granted orphan drug designation to its EZH2-inhibitor tazemetostat for the treatment of adults with INI1-negative epithelioid sarcoma. The designation gives the company market exclusivity for soft tissue sarcomas beyond ...
Leggi tutto

FDA Approves Subcutaneous Rituximab for Blood Cancers

June 22, 2017 - The FDA has approved subcutaneous rituximab for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic ...
Leggi tutto